GLP1R and diabetes mellitus: Considering that diabetes and CKD are both recognized as diseases that increase susceptibility to infection and are associated with poor outcomes following sepsis [32,41,42], it is plausible that incretin-based therapy could improve outcomes by decreasing excessive inflammation and microvascular thrombosis in sepsis via GLP-1 receptor activation [32,43,44].